Premium
Analysis Of Ciprofloxacin Induced Evolutionary Changes In E. coli
Author(s) -
Santos Elana,
Khalpari Omid,
Holden Todd,
Gadura Nidhi
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.491.3
Subject(s) - dna gyrase , ciprofloxacin , topoisomerase iv , topoisomerase , quinolone , genetics , gene , biology , population , antibiotics , dna replication , dna , escherichia coli , mutation , function (biology) , microbiology and biotechnology , medicine , environmental health
This study is designed to look at microbial evolutionary changes in E. coli brought about using a controlled dosage of the antibiotic ciprofloxacin as the selective pressure. The evolutionary changes were studied using bioinformatics. Wildtype (drug sensitive) E. coli was grown in a medium containing a low concentration of ciprofloxacin in order to keep the population stable over the course of several hundred generations. Ciprofloxacin is a type of quinolone antibiotic that binds to and interferes with the function of topoisomerases. Gyrase is a type of topoisomerase, an essential enzyme that unwinds DNA during replication. Mutations in genes GyrA or GyrB can prevent DNA replication. We used PCR to amplify both of these genes and analyze their sequences to reveal if long term exposure to ciprofloxacin has induced any mutations. Various drug resistant strains will also be isolated, the GyrA and GyrB DNA sequenced and analyzed to look for mutations. The presenter is a NIH‐Bridges student and the project is partially funded by CUNY – CCIRG grant.